Pacifico F, Liguoro D, Montuori N, Mellone S, Macchia V, Formisano S, Consiglio E, Di Jeso B
Centro di Endocrinologia ed Oncologia Sperimentale G Salvatore, CNR, Naples, Italy.
Thyroid. 2000 Mar;10(3):201-9. doi: 10.1089/thy.2000.10.201.
We have recently shown that the rat hepatic lectin (RHL)-1 subunit of the asialoglycoprotein receptor (ASGPr) is expressed in the PC C13 differentiated thyroid cell line. To investigate in vivo the expression of RHL-1 and the ability of thyrotropin (TSH) to modulate its expression, reverse-transcriptase polymerase chain reaction (RT-PCR) and Western blot assays have been performed on thyroid extracts from rats treated with thyroxine (T4) or propylthiouracil (PTU), each of which modulates TSH levels. It is shown that RHL-1 expression is down-regulated by T4 (which decreases serum TSH) and upregulated by PTU (which increases serum TSH), at both mRNA and protein levels. The sensitivity of RHL-1 to neoplastic transformation of thyroid cells has been investigated. The RHL-1 expression pattern has been studied in PC C13 thyroid cells transformed by several oncogenes that induce different degrees of malignancy and dedifferentiation. RT-PCR and Western blot assays show that RHL-1 expression progressively decreases as PC C13 cells acquire a more transformed phenotype. Expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA, a housekeeping gene used as internal control to normalize RHL-1 mRNA content, exhibits no variations in the different PC C13 cell lines used. In addition, we show that both native and asialo-thyroglobulin (Tg) bind RHL-1 in vitro, and native Tg binds RHL-1 on the surface of PC C13 cells. After thyroid cells transformation, the surface expression of RHL-1 is inhibited in a measure that correlates with the mRNA and protein levels. Therefore, the RHL-1 inhibition at the mRNA, protein and plasma membrane expression follows a gradient that parallels the progressive acquisition of the fully transformed phenotype in the PC C13 system. The results reported in the present article, together with our previous data, suggest that RHL-1 expression could be regulated, at least in part, by the same transcription factors involved in the expression of the other molecules characteristic of the thyroid differentiated state.
我们最近发现,去唾液酸糖蛋白受体(ASGPr)的大鼠肝凝集素(RHL)-1亚基在PC C13分化甲状腺细胞系中表达。为了在体内研究RHL-1的表达以及促甲状腺激素(TSH)调节其表达的能力,我们对用甲状腺素(T4)或丙硫氧嘧啶(PTU)处理的大鼠的甲状腺提取物进行了逆转录聚合酶链反应(RT-PCR)和蛋白质印迹分析,这两种药物均可调节TSH水平。结果显示,在mRNA和蛋白质水平上,RHL-1的表达受到T4(降低血清TSH)的下调和PTU(升高血清TSH)的上调。我们研究了RHL-1对甲状腺细胞肿瘤转化的敏感性。在由几种诱导不同程度恶性和去分化的癌基因转化的PC C13甲状腺细胞中,研究了RHL-1的表达模式。RT-PCR和蛋白质印迹分析表明,随着PC C13细胞获得更具转化性的表型,RHL-1的表达逐渐降低。用作内对照以标准化RHL-1 mRNA含量的管家基因甘油醛-3-磷酸脱氢酶(GAPDH)mRNA的表达在所用的不同PC C13细胞系中未显示出变化。此外,我们表明天然和去唾液酸甲状腺球蛋白(Tg)在体外均与RHL-1结合,并且天然Tg在PC C13细胞表面与RHL-1结合。甲状腺细胞转化后,RHL-1的表面表达受到抑制,其程度与mRNA和蛋白质水平相关。因此,RHL-1在mRNA、蛋白质和质膜表达上的抑制遵循一种梯度,该梯度与PC C13系统中完全转化表型的逐渐获得平行。本文报道的结果以及我们之前的数据表明,RHL-1的表达至少部分地可能受参与甲状腺分化状态其他特征分子表达的相同转录因子调节。